|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
70,932,000 |
Market
Cap: |
2.94(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$15.81 - $52.44 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on changing the paradigm for the treatment of rare genetic diseases of obesity, which are characterized by early-onset, severe obesity and hyperphagia, a pathological and insatiable hunger. Co. is developing IMCIVREE (setmelanotide) as a medicine strategy for a subset of individuals who have severe obesity due to genetic variants that impair the melanocortin-4 receptor pathway, a pathway in the brain that is responsible for regulating hunger, caloric intake and energy expenditure, which consequently affect body weight.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
22,587 |
269,851 |
390,685 |
429,469 |
Total Sell Value |
$904,227 |
$11,716,886 |
$15,609,906 |
$16,448,857 |
Total People Sold |
2 |
7 |
7 |
8 |
Total Sell Transactions |
3 |
29 |
42 |
61 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Foley Todd |
Director |
|
2020-05-20 |
4 |
AS |
$20.01 |
$210,645 |
I/I |
(10,527) |
2,197,368 |
|
13% |
|
Foley Todd |
Director |
|
2020-05-19 |
4 |
AS |
$20.00 |
$52,660 |
I/I |
(2,633) |
2,207,895 |
|
17% |
|
Foley Todd |
Director |
|
2020-05-18 |
4 |
AS |
$20.00 |
$426,980 |
I/I |
(21,349) |
2,210,528 |
|
21% |
|
Foley Todd |
Director |
|
2020-05-13 |
4 |
AS |
$20.04 |
$36,813 |
I/I |
(1,837) |
2,231,877 |
|
37% |
|
Foley Todd |
Director |
|
2020-05-12 |
4 |
AS |
$20.23 |
$492,439 |
I/I |
(24,342) |
2,233,714 |
|
28% |
|
Foley Todd |
Director |
|
2020-05-11 |
4 |
AS |
$20.34 |
$450,633 |
I/I |
(22,155) |
2,258,056 |
|
31% |
|
Foley Todd |
Director |
|
2020-05-08 |
4 |
AS |
$20.05 |
$132,992 |
I/I |
(6,633) |
2,280,211 |
|
48% |
|
Foley Todd |
Director |
|
2020-05-07 |
4 |
AS |
$20.01 |
$4,002 |
I/I |
(200) |
2,286,844 |
|
50% |
|
Foley Todd |
Director |
|
2020-05-06 |
4 |
AS |
$20.00 |
$32,520 |
I/I |
(1,626) |
2,287,044 |
|
60% |
|
Foley Todd |
Director |
|
2020-04-29 |
4 |
AS |
$20.12 |
$410,388 |
I/I |
(20,397) |
2,288,670 |
|
53% |
|
Foley Todd |
Director |
|
2020-04-28 |
4 |
AS |
$20.07 |
$317,628 |
I/I |
(15,826) |
2,309,067 |
|
49% |
|
Foley Todd |
Director |
|
2020-04-01 |
4 |
AS |
$15.10 |
$233,476 |
I/I |
(15,462) |
2,324,893 |
|
26% |
|
Foley Todd |
Director |
|
2020-03-31 |
4 |
AS |
$15.16 |
$289,677 |
I/I |
(19,108) |
2,340,355 |
|
31% |
|
Smith Hunter C |
CFO and Interim CEO |
|
2020-03-30 |
4 |
OE |
$6.88 |
$26,832 |
D/D |
3,900 |
29,650 |
|
- |
|
Foley Todd |
Director |
|
2020-03-26 |
4 |
AS |
$15.04 |
$34,592 |
I/I |
(2,300) |
2,359,463 |
|
29% |
|
Foley Todd |
Director |
|
2020-03-20 |
4 |
AS |
$15.00 |
$16,500 |
I/I |
(1,100) |
2,361,763 |
|
36% |
|
Foley Todd |
Director |
|
2020-03-19 |
4 |
AS |
$15.07 |
$123,574 |
I/I |
(8,200) |
2,362,863 |
|
41% |
|
Foley Todd |
Director |
|
2020-03-18 |
4 |
AS |
$15.14 |
$193,504 |
I/I |
(12,781) |
2,371,063 |
|
49% |
|
Foley Todd |
Director |
|
2020-03-17 |
4 |
AS |
$15.12 |
$145,953 |
I/I |
(9,653) |
2,383,844 |
|
42% |
|
Smith Hunter C |
Chief Financial Officer |
|
2020-03-13 |
4 |
OE |
$6.88 |
$24,080 |
D/D |
3,500 |
25,750 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2020-03-09 |
4 |
OE |
$6.14 |
$20,925 |
D/D |
3,408 |
558,250 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2020-02-10 |
4 |
OE |
$6.14 |
$41,850 |
D/D |
6,816 |
554,283 |
|
- |
|
Smith Hunter C |
Chief Financial Officer |
|
2020-01-28 |
4 |
OE |
$6.88 |
$43,000 |
D/D |
6,250 |
22,250 |
|
- |
|
Gottesdiener Keith Michael |
CEO & President |
|
2020-01-08 |
4 |
OE |
$4.59 |
$151,800 |
D/D |
33,072 |
546,914 |
|
- |
|
Desikan Nithya |
Chief Commercial Officer |
|
2019-12-27 |
4 |
AS |
$22.79 |
$801,771 |
D/D |
(35,181) |
29,068 |
|
- |
|
253 Records found
|
|
Page 7 of 11 |
|
|